컨텐츠 내용을 수정할 수 있습니다
Instead of just memorizing drug names, we'll connect pulse, blood pressure, electrolytes, kidney function, and bleeding risk before and after administration to distinguish the moments when you need to hold, report, or respond to an emergency.
Core Goal: We make decisions in this order: Verify indication & order → Check pulse & BP → Check K, Mg, & kidney function → Assess bleeding & procedure plans → Administer → Re-evaluate therapeutic effect & toxicity.
We avoid simple rules like "it's a heart drug, so just check the pulse," "all blood thinners need an INR check," or "you must completely stop eating green vegetables." Even with the same drug, the safe action changes depending on the route, kidney function, concurrent medications, scheduled procedures, and current symptoms.
Beta-blockers, some calcium channel blockers, digoxin, and antiarrhythmics can cause bradycardia and conduction disturbances.
Think about how ACEIs, ARBs, nitrates, and diuretics connect to hypotension, dizziness, decreased renal perfusion, and fall risk.
Loop and thiazide diuretics can lower K and Mg, while ACEIs, ARBs, and spironolactone can raise K.
For digoxin, many anticoagulants, and RAAS drugs, changes in creatinine and eGFR alter the risk of drug accumulation, bleeding, and hyperkalemia.
Antiplatelets and anticoagulants have different targets, but you always assess both the risk of bleeding and the risk of clotting if they are stopped.
Distinguish between IV and PO, the first dose and maintenance doses, pre/post-procedure timing, and acute symptoms versus preventive goals.
8 questions to ask before giving a cardiovascular drug
When deciding whether to hold a drug, don't apply one textbook number to every patient.
The parameters differ for adults and children, by indication, underlying rhythm, drug class, and prescribed hold criteria. First, check the patient's status, then cross-reference it with the specific order's hold parameters and your institution's protocol. If there's an abnormality, report it before giving the drug.
| Drug Class | Expected Effect | Key Risks | Nursing Connection |
|---|---|---|---|
| ACE inhibitor -pril | Lowers BP & afterload; treats heart failure & post-MI | Dry cough, hypotension, hyperkalemia, worsening kidney function, angioedema, fetal toxicity | Check BP, K, creatinine/eGFR, pregnancy status, and for any face, lip, tongue, or airway symptoms |
| ARB -sartan | Blocks RAAS; can be an alternative if ACEI is not tolerated | Hypotension, hyperkalemia, worsening kidney function, rare angioedema, fetal toxicity | Having less cough does not mean the risks to K, kidneys, and pregnancy disappear |
| Aldosterone antagonist spironolactone | Excretes Na & water, spares K; treats heart failure, hypertension, and edema | Hyperkalemia, hypotension/dehydration, worsening kidney function, gynecomastia | Check kidney function and for concurrent use of K supplements, K-containing salt substitutes, and ACEIs/ARBs |
If you see swelling of the lips, tongue, or throat, a hoarse voice, or stridor, don't wait, thinking it's just a common ACEI side effect.
Stop the drug and prioritize an airway and breathing assessment, connecting this to an emergency response. A dry cough is uncomfortable, but its urgency is different from angioedema. If pregnancy is confirmed or suspected, do not continue the RAAS drug on your own; immediately check with the prescriber for an alternative.
| Drug Class | Main Action | What to Check | Oversimplifications to Avoid on the Exam |
|---|---|---|---|
| Beta-blocker -lol | Decreases heart rate, contractility, and blood pressure | Pulse, BP, worsening heart failure, bronchoconstriction, masking of hypoglycemia warning signs | Don't stop abruptly; having asthma doesn't mean every drug in the class carries the same risk |
| Diltiazem · verapamil | Decreases AV node conduction and heart rate | Pulse, BP, ECG, heart block, heart failure, constipation with verapamil | Don't lump dihydropyridine CCBs and rate-control CCBs into one category when studying |
| Digoxin | Increases contractility, slows AV node conduction | Apical pulse, ECG, K·Mg·Ca, renal function, toxicity symptoms | Don't rule out toxicity just because the serum level alone is normal |
| Antiarrhythmic | Modulates conduction, refractory period, and automaticity | Original rhythm, QT/QRS, K·Mg, drug-specific long-term toxicity | Don't use the same drug for every tachycardia — first assess stability, QRS width, and presence of a pulse |
Hold & Report Clues: If new dizziness, syncope, chest pain, hypotension, symptomatic bradycardia, progressive heart block, acute pulmonary edema, or new wheeze appears, don't just give the routine dose. Compare the ECG against the prescribed parameters and report immediately.
First, see if the chest pain is new or different from usual, persists at rest, or comes with dyspnea, diaphoresis, nausea, syncope, or neurological symptoms.
Check BP and signs of hypoperfusion before administration, and have the patient sit or lie down to prevent falls and syncope.
Always verify whether the patient is taking PDE-5 inhibitors like sildenafil, tadalafil, vardenafil, avanafil, or riociguat.
SL tablets dissolve under the tongue — don't chew or swallow them. Spray, patch, and IV forms have different purposes and instructions for use.
After the first prescribed dose, reassess pain, BP, level of consciousness, and breathing. If pain persists, worsens, or feels different than usual, don't delay activating EMS.
Keep in the original container, tightly sealed. The patch is not a rescue medication for acute chest pain, and maintain a nitrate-free interval as prescribed.
Never give nitrates together with a PDE-5 inhibitor or sGC stimulator.
This can cause severe hypotension, syncope, and myocardial ischemia. Confirm exactly when the last dose was taken and follow your facility's protocol and the prescriber's judgment. A headache can be common, but hypotension, syncope, or persistent chest pain are not the same level of reaction.
| Drug | Electrolyte Trend | Key Assessments | High-Risk Connections |
|---|---|---|---|
| Furosemide loop | K·Mg·Na can decrease | BP, I/O, daily weight, edema·crackles, K·Mg·Na, renal function | Hypokalemic arrhythmias, dehydration·AKI; risk of ototoxicity increases with rapid IV push, high doses, or decreased renal function |
| Thiazide | K·Na can decrease, Ca conserved | BP, Na·K, glucose, uric acid, volume status | Hyponatremic confusion·seizures, hypokalemia, possible worsening of gout·hyperglycemia |
| Spironolactone | K can increase | K, creatinine/eGFR, BP, volume status | Hyperkalemia risk rises with ACEI·ARB·K supplements·salt substitutes |
Diet is not an automatic prescription. Not everyone on furosemide needs a high-potassium diet, and not everyone on spironolactone must avoid all fruits and vegetables. Personalize the plan by checking the current K level, renal function, concurrent medications, and any prescribed supplementation plan.
Check for new-onset anorexia, nausea·vomiting, or abdominal pain
Bradycardia, AV block, new atrial·ventricular arrhythmias, and palpitations
Fatigue·confusion, blurred vision, changes in color perception·halos are toxicity clues
Older age, decreased renal function, low K·low Mg, high Ca, interacting drugs
Count the rhythm and rate for a full minute, then compare it against the prescribed hold parameters.
Ask whether nausea, loss of appetite, confusion, vision changes, or palpitations feel different from usual.
Low potassium and low magnesium make the heart muscle more sensitive, and reduced kidney function increases drug accumulation.
If you suspect toxicity, hold the next dose and connect the dots — order an ECG, check electrolytes, kidney function, and serum drug levels.
For life-threatening arrhythmias, hyperkalemia, or an unstable patient, prepare emergency treatment like digoxin immune Fab right away.
Don't mix up the hypokalemia risk in chronic digoxin toxicity with the hyperkalemia seen in massive acute overdose.
The clinical context and timeline are different. Don't automatically give potassium just based on one lab value — check the ECG, symptoms, kidney function, and the ingested dose, and confirm the orders with the prescriber.
| System | Warning clues | Monitoring and actions |
|---|---|---|
| Lungs | New dry cough, progressive dyspnea, fever, hypoxia | Report immediately; confirm the plan for baseline and follow-up chest imaging and pulmonary function tests |
| Liver | Fatigue, loss of appetite, right upper quadrant discomfort, jaundice, dark urine | Check baseline and periodic transaminases along with clinical symptoms |
| Thyroid | Changes in weight, heat sensitivity, heart rate, or fatigue | Follow TSH and related thyroid function tests as scheduled |
| Heart | Bradycardia, syncope, QT prolongation, new arrhythmia | Get an ECG, correct K, Mg, and Ca, and reassess rate and rhythm |
| Eyes, skin, nerves | Visual field changes, photosensitivity, blue-gray skin discoloration, tremor, ataxia | Protect from sunlight; report any new visual or neurological symptoms right away |
| Interactions | Concurrent use of warfarin, digoxin, etc. | Check INR and digoxin-related assessments with the prescriber and pharmacist, and confirm whether dose reductions are needed |
Heads-up: The FDA label for oral amiodarone warns that because of serious lung, liver, and proarrhythmic toxicity, it should be used under specialist supervision for life-threatening ventricular arrhythmias only. Don't assume the IV and PO indications and monitoring are the same — always check the current order and protocol.
| Class | Main target | Common drugs | Key nursing points |
|---|---|---|---|
| Antiplatelets | Platelet activation and aggregation | Aspirin, clopidogrel | Think ACS, stents, and arterial clot prevention; watch for GI and intracranial bleeding, and know the risks of stopping DAPT |
| Anticoagulants | Clotting factors, thrombin, factor Xa | Heparin, enoxaparin, warfarin, apixaban, rivaroxaban, dabigatran | Know the indication — AF, VTE, valves, etc. — and check drug-specific labs, kidney function, antidotes, and procedure planning |
| Thrombolytics | Break down already-formed fibrin clot | Alteplase, etc. | A separate high-risk treatment that requires strict time windows, contraindication screening, and bleeding surveillance |
| Item | Unfractionated heparin | LMWH (e.g., enoxaparin) |
|---|---|---|
| Route and features | IV infusion or SC; fast onset, short half-life | Mainly SC; more predictable dose response |
| Labs | For therapeutic infusion, follow aPTT or anti-Xa per institutional protocol, plus CBC and platelets | Not titrated by routine aPTT; anti-Xa may be considered in selected high-risk groups |
| Kidneys | Relatively quick to adjust or stop | Caution with accumulation and dose adjustment when kidney function is reduced |
| Antidote | Reversible with protamine | Protamine may have only partial effect |
| Major risks | Bleeding, thrombocytopenia, HIT/HITT, spinal/epidural hematoma | |
If platelets drop significantly and a new clot appears, don't just look for bleeding — suspect HIT.
Stop all heparin exposure immediately and report to the prescriber and pharmacist so they can connect you with an alternative non-heparin anticoagulant and the right lab work. Simply starting warfarin alone right away can be dangerous in early HIT, so follow the expert protocol.
Check the target range for the specific indication with the prescription, and look at recent changes along with any bleeding or clotting symptoms — don't just focus on a single value.
We don't completely ban vitamin K-rich green vegetables. Teach patients not to suddenly make big changes to their usual intake.
When starting or stopping antibiotics, antifungals, amiodarone, NSAIDs, new OTC products, herbal medicines, or supplements, always check the INR plan.
Make sure patients know to seek immediate evaluation for melena, hematuria, persistent nosebleeds, hematemesis, severe headache, falls, or head trauma.
It's contraindicated in most pregnancies. For pre-procedure discontinuation and bridging, the prescriber decides based on weighing thrombotic risk against bleeding risk.
In life-threatening bleeding, prepare for urgent reversal per protocol: discontinue warfarin, give IV vitamin K and 4-factor PCC.
Don't stick to a rigid rule like "always stop warfarin 5 days before a procedure."
It depends on the type of procedure, INR, indication, presence of a mechanical valve, recent thrombosis, AF stroke risk, and bleeding risk. Confirm a clear plan from the procedure team and the anticoagulation prescriber so the patient doesn't stop it on their own or double up on doses.
| Drug class | Representative drugs | Routine lab caution | Essential checks |
|---|---|---|---|
| Direct Xa inhibitor | apixaban, rivaroxaban, edoxaban | Do not use INR to adjust the dose | CBC, renal and hepatic function, adherence, bleeding, interacting drugs, timing of procedures |
| Direct thrombin inhibitor | dabigatran | No routine INR adjustment | Renal function, bleeding, capsule handling and storage, timing of procedures, adherence |
DOAC safety sentences
Check airway, breathing, BP, pulse, level of consciousness, skin perfusion, and signs of shock. Secure large-bore IV access and activate emergency support.
Look beyond external bleeding — check GI, GU, retroperitoneal, intracranial, surgical sites, and occult bleeding.
Confirm the exact antithrombotic agent, the time of the last dose or infusion, the dose itself, any overlapping medications, and renal and hepatic function.
Prepare CBC with platelets, coagulation tests, renal and hepatic function, type and screen, and urgent imaging based on the symptoms.
Apply the appropriate reversal based on severity and the specific drug: protamine, vitamin K plus 4F-PCC, idarucizumab, andexanet alfa, or your institution's PCC protocol.
Once bleeding is controlled, the decision to restart anticoagulation and the timing of it requires a multidisciplinary re-evaluation of the original indication, thrombotic risk, and re-bleeding risk.
| Drug | Typical urgent reversal | Key caution |
|---|---|---|
| UFH | Protamine | Dose is based on the amount and timing of recent administration; watch for reactions from giving it too fast |
| LMWH | Protamine | Reversal may be incomplete |
| Warfarin | IV vitamin K + 4-factor PCC | For rapid INR correction in life-threatening bleeding; vitamin K alone does not work immediately |
| Dabigatran | Idarucizumab | Check renal function, last dose, and whether it's a major bleed |
| Apixaban and rivaroxaban | Andexanet alfa | Indicated for life-threatening or uncontrolled bleeding; check availability, thrombotic risk, and institutional protocol |
After taking lisinopril, the patient's lips and tongue became swollen and their voice changed. Hold the medication, immediately assess airway and breathing, and call for emergency response. Don't just stop at cough education.
A patient with chest pain tells you they took tadalafil today. Do not administer nitroglycerin. Assess BP and symptoms, then immediately connect with the prescriber and emergency protocol.
A patient on furosemide and digoxin has new nausea, yellow-tinged vision, irregular bradycardia, and low K. Hold digoxin, check ECG, electrolytes, kidney function, and serum level, then prepare for toxicity management.
The patient uses a potassium supplement and a K-containing salt substitute every day. Stop the extra intake, assess K, kidney function, muscle weakness, and arrhythmia symptoms, then verify the prescription.
During a heparin infusion, platelets dropped significantly from baseline and new unilateral leg pain developed. Stop all heparin exposure, immediately report HIT/HITT, and connect to an alternative anticoagulation strategy.
A patient on warfarin shows melena, hypotension, and dizziness. Support ABCs and circulation, prepare INR, CBC, type and screen, and activate the major bleeding reversal protocol.
An epidural procedure is scheduled for a patient on apixaban, but the timing of the last dose is unclear. Do not proceed with the procedure. Confirm with the prescriber and procedure team, reviewing the drug-specific withholding interval and kidney function.
A patient on long-term amiodarone complains of a new dry cough and dyspnea on exertion. Don't just attribute it to aging or heart failure. Immediately report the possibility of pulmonary toxicity and connect to oxygenation, chest, and pulmonary function assessments.
| Risky Oversimplification | Safe Correction |
|---|---|
| ARBs are different from ACEIs, so you don't need to check K or kidneys | Cough is less common, but keep monitoring for hyperkalemia, kidney function, hypotension, and pregnancy risk |
| If it's furosemide, always recommend a banana | Decide based on current K, kidney function, concurrent medications, and the prescribed supplementation plan |
| If the digoxin level is within range, it's not toxicity | Interpret symptoms, ECG, electrolytes, kidney function, and the timing of the blood draw together |
| DOACs require no routine testing or education | INR titration isn't needed, but CBC, kidney, liver, bleeding, adherence, and procedure planning are essential |
| Patients on warfarin must stop eating green vegetables | Keep vitamin K intake consistent without making sudden changes |
| Taking an anticoagulant means no new clots can form | Re-evaluate for worsening symptoms, missed doses, interactions, and dosage appropriateness |
| If there's bleeding, look for the antidote name first | First, bundle ABCs, bleeding location, severity, last dose, and kidney function, then move to drug-specific reversal |
10-Second Final Check
Evidence Scope: This summary was independently written based on the NCSBN 2026 NCLEX-RN Test Plan, NIH DailyMed labels for lisinopril, spironolactone, furosemide, nitroglycerin, digoxin, amiodarone, heparin, warfarin, apixaban labels, and the 2023 ACC/AHA/ACCP/HRS AF guideline.
Only the exam topics and learning weak points were identified from the local feedback PDF. Original questions, answer choices, correct answer wording, tables, images, and layouts were not replicated.
Study-only boundary: Actual administration, holding parameters, doses, interruption intervals, and reversal agent choices depend on the patient's indication, vital signs, renal/hepatic function, time of last dose, procedure type, and institutional protocol. This material does not replace prescriber, pharmacist, or specialist judgment.
다음 이론을 계속 학습하려면 로그인하세요.
로그인하고 계속 학습필기노트, 하이라이터, 메모는 잘 쓰고 있어?
내보내줘운영진이 검토할게요!
마이페이지에서 차단한 회원을 관리할 수 있어요.